{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:26:49Z","timestamp":1774049209253,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.10.014","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T17:18:00Z","timestamp":1604423880000},"page":"242-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-6616","authenticated-orcid":false,"given":"Tobias","family":"Berg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-3040","authenticated-orcid":false,"given":"Maj-Britt","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik H.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Al-Rawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kenholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.10.014_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mrtumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.breast.2020.10.014_bib2","first-page":"707","volume":"vol. 244","author":"Slamon","year":"1989"},{"key":"10.1016\/j.breast.2020.10.014_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/0284186X.2015.1128119","article-title":"Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment","volume":"55","author":"Jensen","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.breast.2020.10.014_bib4","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.breast.2020.10.014_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab - mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.014_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.014_bib7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.014_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2020.10.014_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.014_bib11","author":"NICE"},{"key":"10.1016\/j.breast.2020.10.014_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.breast.2020.10.014_bib13","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2020.10.014_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib15","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","author":"Swain","year":"2013","journal-title":"Lancet Oncol Published Online First"},{"key":"10.1016\/j.breast.2020.10.014_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-020-05599-1","article-title":"Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2\/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)","volume":"181","author":"Greenwell","year":"2020","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.10.014_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OTT.S157634","article-title":"Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting","volume":"11","author":"Wu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.breast.2020.10.014_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41416-019-0480-z","article-title":"The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars","volume":"121","author":"Barbier","year":"2019","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2020.10.014_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","article-title":"The language of biosimilars: clarification, definitions, and regulatory aspects","volume":"77","author":"Declerck","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.breast.2020.10.014_bib22","unstructured":"Medicines Agency E. Biosimilars in the EU - information guide for healthcare professionals."},{"key":"10.1016\/j.breast.2020.10.014_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2017.74.0126","volume":"36","author":"Pivot","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/0284186X.2017.1327720","article-title":"Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study","volume":"56","author":"Cronin-Fenton","year":"2017","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.breast.2020.10.014_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/0284186X.2017.1404638","article-title":"The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007\u20132016","author":"Jensen","year":"2018","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.breast.2020.10.014_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A\u00a0new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.breast.2020.10.014_bib27","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib28","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology\/college of American pathologists guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2020.10.014_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1186\/s12885-019-6132-0","article-title":"Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2020.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e12108","article-title":"Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer","volume":"37","author":"Hall","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e18111","article-title":"Impact of dual anti-HER2 therapy on pathologic complete response rate in breast cancer in a minority-enriched population","volume":"37","author":"Li","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.014_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000354253","article-title":"Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications","volume":"8","author":"Giuliano","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2020.10.014_bib34","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:38Z","timestamp":1760777018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977620302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":34,"alternative-id":["S0960977620302058"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.014","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}